Dose-dependent response of cerebral blood flow in healthy volunteers following administration of β2-adrenergic receptor agonist clenbuterol
Courtney A. Bishop1, Thomas Lodeweyckx2, Jan de Hoon2, Koen Van Laere3,4, Michel Koole4, Wim Vandenberghe5, Gaia Rizzo1, Eugenii Rabiner1,6, Renee Martin7, Anthony Ford7, and Gabriel Vargas7
1Invicro, London, United Kingdom, 2Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 3Division of Nuclear Medicine, University Hospital Leuven, Leuven, Belgium, 4Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium, 5Department of Neurology, University Hospital Leuven, Leuven, Belgium, 6Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, United Kingdom, 7CuraSen Therapeutics, San Carlos, CA, United States
Initial evidence is provided for central effects of the β2-AR agonist clenbuterol on CBF in healthy volunteers. Regions showing particular effect (the hippocampus and thalamus) are associated with cognition and neurodegeneration in Parkinson’s and Alzheimer’s Disease, so similar targeting of β2-AR may prove beneficial in these conditions. Further work is required to determine the extent of central mediation of the effect of β2-AR agonism with clenbuterol in healthy volunteers.
This abstract and the presentation materials are available to members only;
a login is required.